Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

Summary

The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Fibromyalgia

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Axsome Therapeutics, Inc.

Last updated on ClinicalTrials.gov

September 4, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites